Dyne Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

05/13

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:

2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY
2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY
Goldman Sachs 47^th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL

A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:

Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635890237"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635890237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635890237?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635890237","market":"us","top_or_hot":-1,"title":"Dyne Therapeutics to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>WALTHAM, Mass., May  13, 2026  (GLOBE NEWSWIRE) -- <u>Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc</u>. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:</p> <ul><li><strong>2026 RBC Capital Markets Global Healthcare Conference</strong>, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY</li><li><strong>2026 Jefferies Global Healthcare Conference</strong>, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY</li><li><strong>Goldman Sachs 47</strong><sup><strong>th</strong></sup><strong> Annual Global Healthcare Conference 2026</strong>, hosting meetings on Tuesday, June 9, 2026 in Miami, FL<br/></li></ul> <p>A live webcast of each fireside chat will be available in the Investors &amp; Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.</p> <p><strong>About Dyne Therapeutics</strong></p> <p>Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and <a href=\"https://laohu8.com/S/META\">Facebook</a>.</p> <p><strong>Contacts:</strong></p> <p><strong>Investors</strong><br/>Mia Tobias<br/>ir@dyne-tx.com <br/>781-317-0353</p> <p><strong>Media</strong><br/>Stacy Nartker <br/>snartker@dyne-tx.com <br/>781-317-1938</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NTNlOTZlMjMtODFiZC00Y2U5LWJhNTAtMTQxNThhMjc2MTkzLTEyMTI0NDUtMjAyNi0wNS0xMy1lbg==/tiny/Dyne-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics to Participate in Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2026-05-13 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>WALTHAM, Mass., May  13, 2026  (GLOBE NEWSWIRE) -- <u>Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc</u>. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:</p> <ul><li><strong>2026 RBC Capital Markets Global Healthcare Conference</strong>, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY</li><li><strong>2026 Jefferies Global Healthcare Conference</strong>, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY</li><li><strong>Goldman Sachs 47</strong><sup><strong>th</strong></sup><strong> Annual Global Healthcare Conference 2026</strong>, hosting meetings on Tuesday, June 9, 2026 in Miami, FL<br/></li></ul> <p>A live webcast of each fireside chat will be available in the Investors &amp; Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.</p> <p><strong>About Dyne Therapeutics</strong></p> <p>Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and <a href=\"https://laohu8.com/S/META\">Facebook</a>.</p> <p><strong>Contacts:</strong></p> <p><strong>Investors</strong><br/>Mia Tobias<br/>ir@dyne-tx.com <br/>781-317-0353</p> <p><strong>Media</strong><br/>Stacy Nartker <br/>snartker@dyne-tx.com <br/>781-317-1938</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NTNlOTZlMjMtODFiZC00Y2U5LWJhNTAtMTQxNThhMjc2MTkzLTEyMTI0NDUtMjAyNi0wNS0xMy1lbg==/tiny/Dyne-Therapeutics-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293878/0/en/Dyne-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","article_id":"2635890237","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635890237","pubTimestamp":1778671800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"WALTHAM, Mass., May  13, 2026  (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","DYN":"戴纳基","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","CNS":"科恩-斯蒂尔斯金融","BK4135":"资产管理与托管银行"},"translate_title":"达因治疗公司将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNS":1,"DYN":1.5},"content_text":"WALTHAM, Mass., May  13, 2026  (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NYGoldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook. Contacts: InvestorsMia Tobiasir@dyne-tx.com 781-317-0353 MediaStacy Nartker snartker@dyne-tx.com 781-317-1938","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}